Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation
dc.contributor.author | Urbanska, Aleksandra Malgorzata | |
dc.contributor.author | Paul, Arghya | |
dc.contributor.author | Bhahena, Jasmine | |
dc.contributor.author | Prakash, Satya | |
dc.date.accessioned | 2015-10-16T14:07:11Z | |
dc.date.available | 2015-10-16T14:07:11Z | |
dc.date.issued | 2010-08 | |
dc.identifier.citation | Urbanska, Aleksandra Malgorzata, Arghya Paul, Jasmine Bhahena, and Satya Prakash. "Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation." International Journal of Inflammation 2010 (2010): 1-10. http://dx.doi.org/10.4061/2010/894972 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/18698 | |
dc.description.abstract | The objective of this study was to examine the ability of a novel microencapsulated probiotic yogurt formulation to suppress the intestinal inflammation. We assessed its anticancer activity by screening interleukin-1, 6, and 12 (IL-1, 6, 12), secretory levels of tumor necrosis factor-alpha (TNF- ), interferon-gamma (IFN- ), prostaglandin , and thromboxane B2 in the digesta obtained from the duodenum, jejunum, proximal, and distal segments of the ileum of C57BL/6J- /J mice. Formulation-receiving animals showed consistently lower proinflammatory cytokines' levels when compared to control group animals receiving empty alginate-poly-L-lysine-alginate (APA) microcapsules suspended in saline. The concentrations of IL-12 found in serum in control and treatment group animals were significant: pg/mL and pg/mL for control and treatment animals, respectively. We determined a significant change in plasma C-reactive protein: ng/mL in control group and ng/mL in treatment group. Western blots showed a 71% downregulation of cyclooxygenase-2 (COX-2) protein in treatment group animals compared to control. These results point to the possibility of using this yogurt formulation in anticancer therapies, in addition to chronic gut diseases such as Crohn's disease, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD) thanks to its inflammation lowering properties. | en_US |
dc.publisher | Hindawi Publishing Corporation | en_US |
dc.relation.isversionof | dx:10.4061/2010/894972 | en_US |
dc.rights | Copyright © 2010 Aleksandra Malgorzata Urbanska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation | en_US |
dc.type | Article | |
kusw.kuauthor | Paul, Arghya | |
kusw.kudepartment | Chemical & Petroleum Engr | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: Copyright © 2010 Aleksandra Malgorzata Urbanska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.